We are live on ! Find out more
JNCE

Jounce Therapeutics, Inc. Common Stock
JNCE

Delisted

JNCE was delisted on the 3rd of May, 2023.

Back to rankings

1 hedge funds and large institutions have $918K invested in Jounce Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less capital invested

Capital invested by funds: $64.1M → $918K (-$63.1M)

99% less funds holding

Funds holding: 84 → 1 (-83)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 83

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
-83
Holders Change %
-98.81%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
83
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
-$9.81M
2
DTC
Deep Track Capital
Connecticut
-$7.88M
3
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$5.85M
4
BlackRock
BlackRock
New York
-$4.71M
5
OM
Opaleye Management
Massachusetts
-$4.21M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
– -$418K -226,160 Closed
Acadian Asset Management
27
Acadian Asset Management
Massachusetts
– -$249K -135,324 Closed
Bank of New York Mellon
28
Bank of New York Mellon
New York
– -$247K -133,680 Closed
VF
29
Virtu Financial
New York
– -$233K -126,209 Closed
Jane Street
30
Jane Street
New York
– -$233K -126,048 Closed
N
31
Nuveen
North Carolina
– -$223K -120,810 Closed
Morgan Stanley
32
Morgan Stanley
New York
– -$222K -119,925 Closed
Susquehanna International Group
33
Susquehanna International Group
Pennsylvania
– -$200K -108,297 Closed
CIC
34
Cornercap Investment Counsel
Georgia
– -$175K -94,783 Closed
BNP Paribas Financial Markets
35
BNP Paribas Financial Markets
France
– -$169K -91,516 Closed
B
36
Bailard
California
– -$167K -90,200 Closed
T. Rowe Price Associates
37
T. Rowe Price Associates
Maryland
– -$149K -80,336 Closed
XT
38
XTX Topco
Cayman Islands
– -$145K -78,190 Closed
Citadel Advisors
39
Citadel Advisors
Florida
– -$144K -77,599 Closed
Two Sigma Investments
40
Two Sigma Investments
New York
– -$143K -77,200 Closed
AllianceBernstein
41
AllianceBernstein
Tennessee
– -$137K -74,000 Closed
PAM
42
Panagora Asset Management
Massachusetts
– -$123K -66,554 Closed
RhumbLine Advisers
43
RhumbLine Advisers
Massachusetts
– -$117K -63,356 Closed
FLC
44
Fifth Lane Capital
Texas
– -$92.5K -50,000 Closed
Two Sigma Advisers
45
Two Sigma Advisers
New York
– -$88.4K -47,800 Closed
Goldman Sachs
46
Goldman Sachs
New York
– -$79.4K -42,922 Closed
Bank of America
47
Bank of America
North Carolina
– -$69.4K -37,513 Closed
FIM
48
Fernwood Investment Management
Massachusetts
– -$59.7K -32,259 Closed
CIBC Private Wealth Group
49
CIBC Private Wealth Group
Georgia
– -$55.5K -30,000 Closed
KAS
50
Kestra Advisory Services
Texas
– -$48.3K -26,100 Closed
1
2
3 4

JNCE Hedge Fund Activity: Q2 2023 in Review

1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Jounce Therapeutics, Inc. Common Stock (JNCE) for Q2 2023, worth a combined $918K — down 99% from $64.1M a quarter earlier.

Sellers outnumbered buyers: 83 funds closed out of JNCE and 0 opened new positions — a net loss of 83 holders — while 1 trimmed existing stakes and 0 added.

The largest seller was Tang Capital Management, exiting entirely with an estimated $9.81M sold.

  • 1 institutional investor held Jounce Therapeutics, Inc. Common Stock (JNCE) as of Q2 2023, down from 84 in Q1 2023.
  • Funds reported $918K of Jounce Therapeutics, Inc. Common Stock stock for Q2 2023, down 99% quarter-over-quarter.
  • 0 funds opened new Jounce Therapeutics, Inc. Common Stock positions in Q2 2023 and 83 closed out, a net change of -83 holders.
  • The largest Jounce Therapeutics, Inc. Common Stock seller in Q2 2023 was Tang Capital Management, an estimated $9.81M sold.

Based on aggregated 13F filings for Q2 2023.